Deutsche Bank Initiates Coverage On Legend Biotech with Buy Rating, Announces Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank has initiated coverage on Legend Biotech (NASDAQ:LEGN) with a Buy rating and set a price target of $60.
May 23, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Deutsche Bank has initiated coverage on Legend Biotech with a Buy rating and a price target of $60, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a $60 price target by Deutsche Bank is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100